December 12, 2016 / 1:43 AM / 8 days ago

BRIEF-Valneva Reports Positive End-Of-Phase 2 Chikungunya Meeting With The U.S. FDA

March 25 (Reuters) - Valneva SE:

* VALNEVA REPORTS POSITIVE END-OF-PHASE 2 CHIKUNGUNYA MEETING WITH THE U.S. FDA; SETS STAGE FOR PHASE 3 STUDY

* STUDY INITIATION AS SOON AS COVID-19 SITUATION PERMITS, CURRENTLY ANTICIPATED FOR Q4 2020

* PRIMARY ENDPOINT ANALYSIS IS EXPECTED SIX MONTHS THEREAFTER

* FINAL ANALYSIS WILL BE CONDUCTED AT DAY 180 (SIX MONTHS AFTER IMMUNIZATION)

* TOTAL DURATION OF STUDY IS EXPECTED TO BE NINE MONTHS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below